TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
P/E ratio for TELA Bio, Inc. (TELA)
P/E ratio as of 2023: -3.24
According to TELA Bio, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -3.24. At the end of 2022 the company had a P/E ratio of -4.22.
P/E ratio history for TELA Bio, Inc. from 2017 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -3.24 |
| 2022 | -4.22 |
| 2021 | -5.13 |
| 2020 | -6.10 |
| 2019 | -5.72 |
| 2018 | -4.11 |
| 2017 | -4.06 |